Volume 11, Number 11—November 2005
Staphylococcus aureus Bacteremia, Europe
|Country||Population† (4)||% population covered by EARSS‡||Blood culture sets/1,000 inhabitants||No. SAB reported to EARSS||No. SAB for country§||SAB/100,000 inhabitants§||% MRSA|
*Only countries that provided hospital background information for at least 60% of the isolates were included; NA, not available.
‡Population coverage rate as calculated from EARSS hospitals that provided background information was adjusted for nonresponding hospitals as follows: population coverage as calculated divided by proportion of isolates with hospital background information.
§The total number of SAB per country was calculated as follows: number of S. aureus isolates in EARSS divided by adjusted proportion of population covered.
¶These rates are grossly underestimated because of the very low blood culturing rate.
- Collignon P, Nimmo GR, Gottlieb T, Gosbell IB. Australian Group on Antimicrobial Resistance. Staphylococcus aureus bacteremia, Australia. Emerg Infect Dis. 2005;11:554–61.
- Tiemersma EW, Bronzwaer SL, Lyytikäinen O, Degener JE, Schrijnemakers P, Bruinsma N, Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis. 2004;10:1627–34.
- European Antimicrobial Resistance Surveillance System. EARSS manual 2004 [cited 2005 July 25]. Available from http://www.earss.rivm.nl
- Central Intelligence Agency. The world fact book 2003 [cited 2005 July 26]. Available from http://www.cia.gov/cia/download2003.htm
- Health Protection Agency. The second year of the Department of Health's mandatory MRSA bacteraemia surveillance scheme in acute trusts in England: April 2002–March 2003. CDR Weekly. 2003;13:1–9. [cited 2005 July 26]. Available from http://www.hpa.org.uk/cdr/archives/2003/cdr2503.pdf